These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28629264)

  • 1. A comparative study of subgroup identification methods for differential treatment effect: Performance metrics and recommendations.
    Alemayehu D; Chen Y; Markatou M
    Stat Methods Med Res; 2018 Dec; 27(12):3658-3678. PubMed ID: 28629264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-Based Recursive Partitioning for Subgroup Analyses.
    Seibold H; Zeileis A; Hothorn T
    Int J Biostat; 2016 May; 12(1):45-63. PubMed ID: 27227717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regularized outcome weighted subgroup identification for differential treatment effects.
    Xu Y; Yu M; Zhao YQ; Li Q; Wang S; Shao J
    Biometrics; 2015 Sep; 71(3):645-53. PubMed ID: 25962845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studying treatment-effect heterogeneity in precision medicine through induced subgroups.
    Sies A; Demyttenaere K; Van Mechelen I
    J Biopharm Stat; 2019; 29(3):491-507. PubMed ID: 30794033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations.
    Huber C; Benda N; Friede T
    Pharm Stat; 2019 Oct; 18(5):600-626. PubMed ID: 31270933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subgroup identification for treatment selection in biomarker adaptive design.
    Lu TP; Chen JJ
    BMC Med Res Methodol; 2015 Dec; 15():105. PubMed ID: 26646831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian credible subgroup identification for treatment effectiveness in time-to-event data.
    Ngo D; Baumgartner R; Mt-Isa S; Feng D; Chen J; Schnell P
    PLoS One; 2020; 15(2):e0229336. PubMed ID: 32101562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finding the best subgroup with differential treatment effect with multiple outcomes.
    Zhao B; Fine J; Ivanova A
    Stat Med; 2024 Jun; 43(13):2487-2500. PubMed ID: 38621856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A general statistical framework for subgroup identification and comparative treatment scoring.
    Chen S; Tian L; Cai T; Yu M
    Biometrics; 2017 Dec; 73(4):1199-1209. PubMed ID: 28211943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A platform for comparing subgroup identification methodologies.
    Ruberg S; Zhang Y; Showalter H; Shen L
    Biom J; 2024 Jan; 66(1):e2200164. PubMed ID: 37147787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generated effect modifiers (GEM's) in randomized clinical trials.
    Petkova E; Tarpey T; Su Z; Ogden RT
    Biostatistics; 2017 Jan; 18(1):105-118. PubMed ID: 27465235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subgroup analysis with semiparametric models toward precision medicine.
    Yuan A; Chen X; Zhou Y; Tan MT
    Stat Med; 2018 May; 37(11):1830-1845. PubMed ID: 29575056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The likelihood as statistical evidence in multiple comparisons in clinical trials: no free lunch.
    Korn EL; Freidlin B
    Biom J; 2006 Jun; 48(3):346-55. PubMed ID: 16845900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision medicine: Subgroup identification in longitudinal trajectories.
    Wei Y; Liu L; Su X; Zhao L; Jiang H
    Stat Methods Med Res; 2020 Sep; 29(9):2603-2616. PubMed ID: 32070237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating covariates information in adaptive clinical trials for precision medicine.
    Zhao W; Ma W; Wang F; Hu F
    Pharm Stat; 2022 Jan; 21(1):176-195. PubMed ID: 34369053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses.
    Wang SV; Jin Y; Fireman B; Gruber S; He M; Wyss R; Shin H; Ma Y; Keeton S; Karami S; Major JM; Schneeweiss S; Gagne JJ
    Am J Epidemiol; 2018 Aug; 187(8):1799-1807. PubMed ID: 29554199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validating effectiveness of subgroup identification for longitudinal data.
    Andrews N; Cho H
    Stat Med; 2018 Jan; 37(1):98-106. PubMed ID: 28948635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bayesian credible subgroups approach to identifying patient subgroups with positive treatment effects.
    Schnell PM; Tang Q; Offen WW; Carlin BP
    Biometrics; 2016 Dec; 72(4):1026-1036. PubMed ID: 27159131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.